The biological drug API manufacturing market is estimated to grow at a CAGR of 9.0% in the first half of the forecast period. In 2017, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry.
How this 209-page report delivers:
• Provides qualitative and quantitative analysis of the leading submarkets the period 2018-2028. Visiongain forecasts revenues and their growth for these submarkets: • Mammalian cell culture • Microbial fermentation • Other expression platforms
• Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2018-2028. Visiongain forecasts contract API drug revenues to 2028 for these individual segments: • Monoclonal antibody (mAb) therapies • Vaccines • Insulin therapies • Interferon therapies • Growth hormones
• Find forecasts of the leading national markets from 2018 to 2028: • The EU, including the five leading markets (UK, Germany, France, Italy and Spain). • The US • Japan • Switzerland • Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.
• Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are: • Boehringer Ingelheim BioXcellence • Celltrion • DSM Biologics • Lonza • Samsung BioLogics • Cytovance Biologics • Fujifilm Diosynth Biotechnologies • Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.
• Provides qualitative analysis: SWOT and STEP Analysis of the biological drug API manufacturing market.
• Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2017, as well as predicted developments for the period to 2028.
• Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2017. The report also contains SWOT and STEP analysis of the industry and market.
• Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.
• 103 charts unavailable elsewhere
Visiongain’s study is intended for anyone requiring commercial analyses for the biological drug API manufacturing market. You find data, trends and predictions.
Buy our report today Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028: Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Contract Biological Drug API Manufacturing: World Market Review 2017
1.2 Benefits of this Report
1.2.1 How This Report Delivers
1.2.2 Main Questions Answered by This Analytical Report
1.3 Who is This Report For?
1.4 Methods of the Study
1.5 Frequently Asked Questions (FAQ)
1.6 Some Associated Reports
1.7 About Visiongain
2. Introduction to Biological drug API Manufacturing Services
2.1 What are Biological drug API Manufacturing Services?
2.1.1 Producing Biological drug API: An Overview of the Manufacturing Process
2.1.2 Defining the Biological drug API Manufacturing Market
2.1.3 Differing Expression Systems to Manufacture APIs
2.2 Challenges in Manufacturing Biological drug API
2.3 Outsourcing: A Common Trend in Biological drug API Manufacturing Services
2.4 Future Trends for the Biological drug API Manufacturing Services Market
3. Biological drug API Manufacturing Services: World Market Outlook and Forecast 2017-2028
3.1 The Contract Biological drug API Manufacturing Services Market Performance, 2017
3.1.1 Contract Biological drug API Manufacturing Services: Forecast 2017-2028
3.2 Drivers and Restraints in the Biological Drug API Manufacturing Services Market
3.2.1 Drivers in the Biological Drug API Manufacturing Market
3.2.1.1 The Ageing Population is a Driver for Growth
3.2.1.2 The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
3.2.1.3 Outsourcing as a Driver for Growth
3.2.1.4 Opportunities from the Long Pipeline Will Drive Growth
3.2.1.5 Increased Investment in Orphan Drugs from Companies
3.2.1.6 Emerging Markets Will Grow and Influence the Market
3.2.1.7 Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
3.2.2 Restraints on Growth in the Biological drug API Manufacturing Services Market
3.2.2.1 Pricing Pressures Will Limit Market Growth
3.2.2.2 Regulatory Restrictions Will Increase
3.2.2.3 Overcapacity Will Be Adverse to Market Growth for CMOs
3.2.2.4 Complexity of API Production is a Challenge
3.3 Outlook for the Outsourced Biological drug API Services: Increased Demand
4. Biological drug API Manufacturing Services Submarkets: World Market Outlook and Forecasts 2017-2028
4.1 Submarkets for the Biological drug API Manufacturing Services Industry
4.1.1 The Mammalian Cell Culture Submarket
4.1.2 The Mammalian Cell Culture Submarket Forecast 2017-2028
4.1.3 ADCs and Next-Generation Antibodies Will Drive Growth 2017-2028
4.1.4 The Microbial Fermentation Submarket
4.1.5 The Microbial Fermentation Submarket Forecast 2017-2028
4.1.5.1 Increase in Demand for Insulin Will Drive Growth 2017-2028
4.1.6 Other APIs Expression Systems Are Still in Development
4.1.6.1 Plant-Made Pharmaceuticals
4.1.6.2 Yeast Cell Expression Systems
4.1.6.3 Insect Cell Expression Systems
4.1.6.4 Other Expression Systems Submarket Forecast 2017-2028
4.2 Chapter Summary: Positive Growth for the Market
5. Biological drug API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors: 2017-2028
5.1 Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
5.1.1 Contract API Monoclonal Antibody Manufacturing Forecast 2017-2028
5.1.2 Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
5.2 Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
5.2.1 Contract API Vaccine Market: Outlook and Forecast 2017-2028
5.2.2 Challenges in Manufacturing Vaccines
5.3 Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
5.3.1 Contract API Insulin Analogues Forecast 2017-2028
5.3.2 Insulin Analogues: In-House Production Restrains Contract API Insulin Therapies Market Growth
5.3.3 Development Trends in the Contract API Insulin Market 2017 to 2028
5.4 Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
5.4.1 Contract API Interferon Market Forecast 2017-2028
5.4.2 Unlikely to be Opportunities in the Contract API Interferon Market
5.5 Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
5.5.1 Contract API Growth Hormone Market Forecast 2017 to 2028
5.5.2 Most Manufacturing is In-House for Growth Hormone Production
5.5.3 Long-Acting Therapies Provide Opportunity for Outsourcing
5.6 Chapter Summary: Outsourcing for Key Biological
Products 2017-2028
6. Leading National Markets for Contract Biological drug API Manufacturing Services 2017-2028
6.1 Regional Breakdown of the World Biological drug API Manufacturing Services Market
6.1.1 US and EU Dominate Growth for Leading National Submarkets 2017-2028
6.1.2 National Revenue Shares by 2028: Emerging Market Growth
6.2 Contract Biological drug API Manufacturing in EU Market 2017-2028
6.2.1 Strong Growth for the EU Revenue Forecasts 2017-2028
6.2.2 Forecasts for Switzerland and Leading EU National Revenues 2017-2028
6.2.2.1 Germany Leads the EU Biotech Market with Strong Growth
6.2.2.2 UK: Strong Research Sector Will Drive Market Growth
6.2.2.3 France: Strong Vaccine Development Industry
6.2.2.4 Switzerland: Headquarters for Leading Companies
6.2.2.5 Spain: Numerous Biotech Companies
6.2.2.6 Italy: Outlook and Forecast 2017-2028
6.2.3 US: A Market Leader in Biological drug API Manufacturing
6.2.4 Japan: A Less Mature Contract Manufacturing Market
6.2.5 BRIC Market: Outlook and Forecasts for Emerging Markets 2017 - 2028
6.2.5.1 Emerging Nations May Develop a Presence in the Biologics Market
6.2.5.2 Increased Demand for Biosimilars and Biological Drugs 2017-2028
6.2.5.3 China is Poised for Growth: Forecast for 2017-2028
6.2.5.4 India Offers a Lower-Cost Advantage for Biological drug API Manufacturing Services: Forecast 2017-2028
6.2.5.5 Brazilian and Russian Governments Promoting Domestic Biotech Development
6.2.5.6 Russian Biological drug API Manufacturing Services Forecast: 2017-2028
6.2.5.7 Brazilian Biological drug API Manufacturing Services Forecast: 2017-2028
6.2.6 South Korea: Market Forecast, 2017-2028
6.2.6.1 Leading CMOs Celltrion and Samsung BioLogics Drive the Market
6.2.7 Singapore: Market Forecast, 2017-2028
6.3 Summary of Chapter: Outlook for Leading National Submarkets 2017-2028
7. Leading CMOs in the Biological drug API Manufacturing Services Market
7.1 Four Companies Led the Market in 2017
7.2 Leading Companies by Capacity
7.2.1 Small-Scale Biopharmaceutical Manufacturing is a Common Trend
7.2.2 Barriers to Market Entry 2017-2028
7.2.2.1 The High Cost of Facilities: Acquisition as a Cheaper Alternative
7.3 FDA Opens Barriers for the Biosimilars Market
7.4 Boehringer Ingelheim BioXcellence
7.4.1 Strategic Outlook: Expanding into the Asian Market
7.5 Celltrion: Biologics Leader in Asia
7.5.1 Celltrion: Likely Target for Mergers and Acquisitions?
Figure 9.1 Contract Biological drug API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2017 - 2028
Figure 9.2 Contract Biological drug API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2018, 2020, 2022, 2024, 2026 and 2028
Abasria
AbbVie
Accord Healthcare
Acquired Cedarburg Pharmaceuticals,
Actavis Generics
Adaptimmune Therapeutics
Agensys
Althera Technologies
Altus Pharmaceuticals
Amgen
Apotex
Aptuit
arGEN-X
Ascendis Pharma A/S
Asterion
Astra Zeneca
Avid Bioservices Inc
Bakhu Pharma.
Banner Life Sciences
Basaglar
Baxalta
Baxter
Bayer
Bever Pharmaceutical
Biocad
Biocon
Biogen
Biogen Idec
BMS
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence
Bolder BioTechnology
Calico Life Science
Caspugel
Catalent Biologics
Celgene
Celldex Therapautics
Celltrion
Cinfa
CMC Biologics
CMIC Holdings Co. Ltd.
CMO Relthy Laboratórios
Cook Pharmica
Critical Pharmaceuticals
CT Arzneimittel
Cytos Biotechnology
Cytovance Biologics
DPx Fine Chemicals
DPx Holdings B.V.
DSM Biologics
DSM Sinochem Pharmaceuticals
Eli Lily
EMD Millipore
Ferring Pharmaceuticals
Filnox Biotech
Fresenius
Fujifilm Diosynth Biotechnologies
Gallus BioPharmaceuticals,
GE Healthcare
Genentech
GeneScience Pharmaceuticals Co., Ltd.
Genexine and Handok
Genmab
Genzyme
Gilead Sciences, Inc.
GSK
Hanmi Pharmaceutical Co.
Hexal
Index Ventures
Infarco
Infinity Pharmaceuticals
Inno Biologics
Innovation Network Corporation of Japan (INCJ),
Johnson and Johnson
Johnson Matthey
JSR Corporation
Kalon Biotherapeutics
KBI Biopharma, Inc.
Kemwell
Kyowa Hakko Kirin
Labrys Biologics Inc,
Laureate Biopharma
LG Life Sciences, Ltd.
Lonza
Matrix Laboratories
Merck
Mitsubishi Gas Chemical Company
Mylan
Neopharm
Nikon
Nippon kayaku
Norbitec
Novartis
Novasep
Novo Nordisk
Nuron Biotech
Nycomed
Opko Health
Patheon
PelChem
Peregrine Pharmaceuticals
Perrigo
Pfizer
Pharmstandard
Phyton Biotech
Piramal Healthcare
Precision Biologics
Progenics
Quintiles
Rebtschler Biotechnologie
Recepta Biopharma
Redwood Bioscience
Rentschler
Rentschler Biotechnologie
Roche
RoYal DSM
SAFC
Samsung BioLogics
Sanofi
SCM Pharma
Seattle Genetics
ShangPharma
SICOR Biotech
Sigma-Aldrich Corporation
Stada
SunShine Biopharma
SynCo BioPartners
Takeda
Teva
Therapure Biopharma
Thermo Fisher
Toyobo Biologics
Transgene SA
Versartis
Vertex
Vida Pharma
VTU
WuXi Biologics,
WuXi PharmaTech
Zhangjiang Biotech
Zhejiang Jiang Yuan Tang Biotechnology
ZJ Base
List of Organisations Mentioned in the Report
FDA
Germany’s Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Japanese Ministry of Health, Labour and Welfare
NHS
NICE
WHO
Download sample pages
Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028
Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
